Abstract:Parkinson's disease impairs the inhibition of responses, and whilst impulsivity is mild for some patients, severe impulse control disorders affect similar to 10% of cases. Based on preclinical models we proposed that noradrenergic denervation contributes to the impairment of response inhibition, via changes in the prefrontal cortex and its subcortical connections. Previous work in Parkinson's disease found that the selective noradrenaline reuptake inhibitor atomoxetine could improve response inhibition, gambling decisions and reflection impulsivity. Here we tested the hypotheses that atomoxetine can restore functional brain networks for response inhibition in Parkinson's disease, and that both structural and functional connectivity determine the behavioural effect. In a randomized, double-blind placebo-controlled crossover study, 19 patients with mild-to-moderate idiopathic Parkinson's disease underwent functional magnetic resonance imaging during a stop-signal task, while on their usual dopaminergic therapy. Patients received 40 mg atomoxetine or placebo, orally. This regimen anticipates that noradrenergic therapies for behavioural symptoms would be adjunctive to, not a replacement for, dopaminergic therapy. Twenty matched control participants provided normative data. Arterial spin labelling identified no significant changes in regional perfusion. We assessed functional interactions between key frontal and subcortical brain areas for response inhibition, by comparing 20 dynamic causal models of the response inhibition network, inverted to the functional magnetic resonance imaging data and compared using random effects model selection. We found that the normal interaction between pre-supplementary motor cortex and the inferior frontal gyrus was absent in Parkinson's disease patients on placebo (despite dopaminergic therapy), but this connection was restored by atomoxetine. The behavioural change in response inhibition (improvement indicated by reduced stop-signal reaction time) following atomoxetine correlated with structural connectivity as measured by the fractional anisotropy in the white matter underlying the inferior frontal gyrus. Using multiple regression models, we examined the factors that influenced the individual differences in the response to atomoxetine: the reduction in stop-signal reaction time correlated with structural connectivity and baseline performance, while disease severity and drug plasma level predicted the change in fronto-striatal effective connectivity following atomoxetine. These results suggest that (i) atomoxetine increases sensitivity of the inferior frontal gyrus to afferent inputs from the pre-supplementary motor cortex; (ii) atomoxetine can enhance downstream modulation of frontal-subcortical connections for response inhibition; and (iii) the behavioural consequences of treatment are dependent on fronto-striatal structural connections. The individual differences in behavioural responses to atomoxetine highlight the need for patient stratification in future clinical trials of noradrenergic therapies for Parkinson's disease.

Reduced locus coeruleus integrity linked to response inhibition deficits in parkinsonian disorders

Locus Coeruleus Integrity Is Linked to Response Inhibition Deficits in Parkinson's Disease and Progressive Supranuclear Palsy

Locus Coeruleus Integrity Correlates with Inhibitory Functions of the Fronto-Subthalamic ‘hyperdirect’ Pathway in Parkinson’s Disease

Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson’s disease

Locus Coeruleus Degeneration is Associated with Disorganized Functional Topology in Parkinson’s Disease

Locus Coeruleus Integrity from 7T MRI Relates to Apathy and Cognition in Parkinson's Disease and Progressive Supranuclear Palsy

Locus Coeruleus Degeneration Correlated with Levodopa Resistance in Parkinson's Disease: A Retrospective Analysis.

Locus Coeruleus Pathology in Progressive Supranuclear Palsy, and Its Relation to Disease Severity

Locus Coeruleus Integrity from 7 T MRI Relates to Apathy and Cognition in Parkinsonian Disorders

Low frequency oscillations in mid-rostral dorsolateral prefrontal cortex support response inhibition.

Selective effects of dopaminergic and noradrenergic degeneration on cognition in Parkinson's disease

Spatiotemporal Neurodegeneration of the Substantia Nigra and Its Connecting Cortex and Subcortex in Parkinson's Disease.

Locus Coeruleus Volume is Reduced in Early Parkinson Disease-Related Orthostatic Hypotension.

Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson's Disease

Functional connectivity alterations in Parkinson’s disease during the stop-signal task

Examining the Role of the Noradrenergic Locus Coeruleus for Predicting Attention and Brain Maintenance in Healthy Old Age and Disease: An MRI Structural Study for the Alzheimer's Disease Neuroimaging Initiative

Reorganization of Cortical Oscillatory Dynamics Underlying Disinhibition in Frontotemporal Dementia.

Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases

Pharmacological and pupillary evidence for the noradrenergic contribution to reinforcement learning in Parkinson's disease

Examining the Role of the Noradrenergic Locus Coeruleus for Predicting Attention and Brain Maintenance in Healthy Old Age and Disease: An MRI Structural Study for the Alzheimer’s Disease Neuroimaging Initiative

Atomoxetine restores the response inhibition network in Parkinson’s disease